Compare General Motors Company (GM) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Johnson & Johnson — how do they compare? General Motors Company trades at $87.14 (market cap $78.40B), while Johnson & Johnson trades at $260.93 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 8× General Motors Company's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| GM | JNJ | |
|---|---|---|
Market Cap | $78.40B | $626.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $267.24 |
52-Week Low | $54.16 | $172.78 |
Enterprise Value | $181.38B | $654.37B |
Dividend Yield | 0.81% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.19, down 0.88% on the day, with strong technical momentum showing bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.57 exceeding the $3.19 estimate. Recent developments include a $4.5 billion parts supply agreement to mitigate future disruptions and a renewed 20-year joint venture with China's SAIC Motor. Analyst consensus remains strongly positive with a $108.82 price target representing 25% upside potential.
GM presents a compelling investment case with attractive valuation metrics including P/S of 0.45 and EV/EBITDA of 10.35, though profitability metrics remain challenged with net margin at 1.05%. Key risks include declining profit margins from 6.33% in 2022 to 1.45% in 2025, high debt levels with debt-to-asset ratio of 46.79%, and ongoing supply chain challenges in the automotive sector.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
